Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

I-MAB - American Depositary Shares (NQ:IMAB)

3.410 -0.100 (-2.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about I-MAB - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares moved upwards by 110.49% to $1.57 during Thursday's regular session. Trading volume for Sonnet BioTherapeutics'... 
Via Benzinga
Why I-MAB's Stock Is Trading Higher Today
I-MAB (NASDAQ:IMAB) shares are trading higher af... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares climbed 63.7% to close at $1.22 on Thursday after dropping 12% on Wednesday. Sonnet BioTherapeutics recently... 
Via Benzinga
I-Mab Stock Is Trading Lower After Unveiling Mid-Stage Trial Data Of Plonmarlimab In Hospitalized COVID-19 Patients
I-Mab (NASDAQ: IMAB) has announced interim data from its Phase 2/3 study evaluating plonmarlimab (TJM2 or TJ003234) for cytokine release syndrome (CRS) in patients... 
Via Benzinga
Week In Review: Kumquat Signs $2 Billion US-China Deal With Lilly For Novel Immune Drugs
Kumquat Biosciences announced a $2 billion agreement with a Lilly subsidiary to discover small molecule drugs that stimulate tumor-specific immune responses in cancer patients. Lilly will make a $70... 
Via Talk Markets
I-Mab To Start Testing Alzheimer's Candidate In Human Trials
The FDA has signed off I-Mab (NASDAQ: IMAB) Investigational New Drug (IND) application for Protollin, an Alzheimer's candidate. Brigham and Women's... 
Via Benzinga
62 Biggest Movers From Yesterday
Gainers Flora Growth Corp. (NASDAQ: FLGC) surged 63.1% to close at $8.27. The Miami-based cannabis producer confirmed Tuesday it has signed a non-binding letter of intent to... 
Via Benzinga
Topics Cannabis
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Infinity Pharmaceuticals (NASDAQ:INFI) shares moved upwards by 45.98% to $2.22 during Wednesday's regular session. As of 12:30 EST, this security is trading at... 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares jumped 59.9% to $2.43. Infinity Pharmaceuticals shares tumbled over 31% on Tuesday after the company highlighted the... 
Via Benzinga
I-Mab Stock Moves Higher As IND For Mid-Stage Efineptakin Cancer Trial Accepted By China
The National Medical Products Administration (NMPA) of China has signed off I-Mab's (NASDAQ: IMAB) IND application to initiate a Phase 2 trial of efineptakin... 
Via Benzinga
Week In Review: Keymed Completes $378 Million IPO In Hong Kong For Antibody Drugs
Keymed Biosciences​​ of Chengdu completed a $378.5 million Hong Kong IPO to develop its portfolio of antibody candidates. The company priced the IPO at the top end of the range, and its shares rose 28%... 
Via Talk Markets
Topics Initial Public Offering
Week In Review: BeiGene Plans $3 Billion IPO On Shanghai STAR Market
BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. It will be the first Chinese biopharma to be listed in Shanghai, Hong Kong, and the US. 
Via Talk Markets
Topics Initial Public Offering
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big... 
Via Benzinga
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Adial Pharmaceuticals (NASDAQ:ADIL 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2021
Upgrades According to Barrington Research, the prior rating for Landec Corp (NASDAQ:LNDC) was changed from Market Perform to Outperform. Landec earned $0.09 in the third... 
Via Benzinga
Stocks That Hit 52-Week Highs On Wednesday
This morning 132 companies reached new 52-week highs. Noteworthy Mentions: The largest company by market cap to break to a new 52-week high was NVIDIA (NASDAQ:NVDA... 
Via Benzinga
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 105 companies hit new 52-week highs. Interesting Facts: Toyota Motor (NYSE:TM) was the largest firm by market cap to set a new 52-... 
Via Benzinga
Mid-Day Market Update: Yext Surges Following Upbeat Q1 Results; 1847 Goedeker Shares Slide
Midway through trading Friday, the Dow traded up 0.33% to 34,578.23 while the NASDAQ rose 0.41% to 13,792.40. The S&P also rose, gaining 0.26% to 4,211.63. The U.S. has the... 
Via Benzinga
Topics Stocks
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) BioCryst Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 20) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Stocks That Hit 52-Week Highs On Thursday
Before 10 a.m. ET Thursday, 56 stocks made new 52-week highs. Intriguing Points: The largest company by market cap to hit a new 52-week high was Novo Nordisk (NYSE:... 
Via Benzinga
I-Mab Showcases Early Data On Uliledlimab/Atezolizumab Combo In Advanced Cancer Settings
I-Mab (NASDAQ: IMAB) unveiled early results from Phase 1 study evaluating uliledlimab in combination with Roche Holdings AG’s (OTC: RHHBY)... 
Via Benzinga
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million... 
Via Talk Markets
I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study
I-Mab (NASDAQ: IMAB) has announced topline results from its Phase 2 study evaluating olamkicept (also known as TJ301) in patients with active... 
Via Benzinga
Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between Two San Diego-China Oncology Biopharmas
Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Both companies develop novel cancer drugs, both are headquartered in San Diego and both have operations in... 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback